HK Stock Market Move | Innovative drug concept stocks fell again. JW Therapeutics (02126) denied "losing money to gain publicity," while institutions are bullish on the in-hospital volume growth of innovative drugs.
Innovative drug concept stocks fell again. As of press time, JW Therapeutics (02126) fell 10.20% to HK$2.42; Ascletis Pharma-B (01672) fell 4.90% to HK$4.465; Kintor Pharmaceutical-B (09939) fell 3.96% to HK$1.335; HBM Holdings-B (02142) fell 2.94% to HK$10.23.
Innovative drug concept stocks fell again. As of press time, JW Therapeutics (02126) fell 10.20% to HK$2.42; ASCLETIS-B (01672) fell 4.90% to HK$4.465; KINTOR PHARMA-B (09939) fell 3.96% to HK$1.335; HBM HOLDINGS-B (02142) fell 2.94% to HK$10.23.
On the news front, a Cailian Press reporter learned that regarding whether JW Therapeutics' price cut on its CAR-T drug for inclusion in the basic medical insurance catalog is "losing money to gain publicity," relevant management of JW Therapeutics recently denied the claim, stating that it was a prudent decision that "opened up room for volume growth on a price basis that still has a profit foundation," and that after entering the medical insurance catalog, the company is very confident in gradually driving the company to profitability.
Sinolink pointed out that the 2026 dual catalogs for basic medical insurance and commercial insurance were released, with 51 Class 1 innovative drugs newly included in basic medical insurance, a record high, and domestic CAR-T has already entered basic medical insurance in the first edition of the commercial insurance catalog. Combined with four departments improving in-hospital provisioning, assessment, and payment arrangements, we are bullish on the in-hospital volume growth of innovative drugs in 2027, with focus on new nationally negotiated products that have clear clinical demand and still have room for improvement in hospital coverage.
Related Articles

Earnings Preview | U.S. retail sales growth slows, "consumer bellwether" Walmart Inc. (WMT.US) faces a major test

JP Morgan: Raises LINK REIT (00823) target price to HK$44.5, maintains "Overweight" rating.

EB SECURITIES: New energy has good structural allocation value; investment opportunities come from certainty improvement in sub-sectors.
Earnings Preview | U.S. retail sales growth slows, "consumer bellwether" Walmart Inc. (WMT.US) faces a major test

JP Morgan: Raises LINK REIT (00823) target price to HK$44.5, maintains "Overweight" rating.

EB SECURITIES: New energy has good structural allocation value; investment opportunities come from certainty improvement in sub-sectors.






